Skip to main content
NCBI home page
Cell Death & Disease logoLink to Cell Death & Disease
. 2019 Oct 22;10(11):796. doi: 10.1038/s41419-019-1966-6

CCL14 serves as a novel prognostic factor and tumor suppressor of HCC by modulating cell cycle and promoting apoptosis

Mengxuan Zhu 1,#, Weiyue Xu 2,#, Chuanyuan Wei 1,#, Jing Huang 2, Jietian Xu 2, Yuye Zhang 2, Yan Zhao 1, Jie Chen 1, Shuangshuang Dong 1, Binbin Liu 1,✉, Chunmin Liang 2,✉
PMCID: PMC6805940  PMID: 31641099

Abstract

CCL14 is a member of CC chemokines and its role in hepatocellular carcinoma (HCC) is still unknown. In this study, CCL14 expression were analyzed by tissue microarray (TMA) including 171 paired tumor and peritumor tissues of patients from Zhongshan Hospital of Fudan University. We found for the first time that CCL14 was downregulated in HCC tumor tissues compared with peritumor tissues (P = 0.01). Meanwhile, CCL14 low expression in HCC tumor tissues is associated with a poor prognosis (P = 0.035). CCL14 also displayed its predictive value in high differentiation (P = 0.026), liver cirrhosis (P = 0.003), and no tumor capsule (P = 0.024) subgroups. The underlying mechanisms were further investigated in HCC cell lines by CCL14 overexpression and knock-down in vitro. We found overexpression of CCL14 suppressed proliferation and promoted apoptosis of HCC cells. Finally, the effect was confirmed by animal xenograft tumor models in vivo. The results shown overexpression of CCL14 lead to inhibiting the growth of tumor in nude mice. Interestingly, our data also implied that CCL14 played these effects by inhibiting the activation of Wnt/β-catenin pathway. These findings suggest CCL14 is a novel prognostic factor of HCC and serve as a tumor suppressor.

Subject terms: Cancer prevention, Diagnostic markers

Introduction

Hepatocellular carcinoma (HCC), one of the most common malignant tumors worldwide, ranks fifth in incidence and second in cancer-related mortality1. The prognosis of HCC remains poor due to its insidious onset and high rate of recurrence after resection. Over the past few years, molecular targeted therapy has been proven to be effective in patients. However, targeted therapy is limited because drug resistance is easily developed. Thus, it is urgent to develop new treatments for HCC.

Chemokines were initially defined as molecular signals to induce leukocyte migration during inflammation, which have been identified and classified into four subfamilies (CXC, CC, CX3C, and C)2. Recently, researchers have demonstrated that CCL2 and CCL5 promote cancer cell proliferation, invasion and metastasis in several tumors3–7.

Consistent with other reports, we have focused on chemokines for years and previously found that secondary lymphoid tissue chemokine (SLC, also named as CCL21) can attract dendritic cells (DCs) to T cells, serving as a treatment for tumor8–11. Moreover, it was also reported that CC chemokine receptor-like 1 play its function as tumor suppressor, which inhibits the proliferation and invasion of HCC cells12.

In this study, we aim to assess the function of CCL14 in HCC. We found low expression of CCL14 in HCC tumor tissues lead to shorter OS. Overexpression of CCL14 by lentivirus can suppress the proliferation and promote the apoptosis of HCC cells, which lead to inhibiting tumor growth in animal xenograft tumor models. Our results also suggest that CCL14 may play these effects by inhibiting the activation of Wnt/β-catenin pathway.

Materials and methods

Clinical samples

Tissue microarray (TMA), including 171 paired tumor and peritumor tissues, was obtained from Zhongshan Hospital, Fudan University (Shanghai, China). All patients were confirmed as HCC by two pathologists independently and underwent complete surgical excision between January 2006 and August 2006. Another 20 pairs of fresh tumor and peritumor tissues were randomly collected from the Liver Cancer Institute at Zhongshan Hospital and analyzed by western blot. This study was approved by the ethics committee of Zhongshan Hospital and informed consent was obtained from each patient.

Immunohistochemistry (IHC)

IHC was performed in TMA as previously described13,14. The immunostaining intensities were semiquantitatively scored as: 0 for negative; 1 for weak; 2 for moderate; 3 for strong by two observers independently. Groups 0 and 1 were classified as low expression, while groups 2 and 3 were classified as high expression.

Cell culture

The HCC cell lines Huh7, SMMC-7721, and HepG2 were purchased from Chinese Academy of Sciences (Cell Bank, Shanghai Institutes for Biological Sciences). The stepwise metastatic HCC cell lines including MHCC97L, MHCC97H, and HCCLM3 were established by the Liver Cancer Institute of Zhongshan Hospital. All cell lines were routinely cultured.

Western blot assay

Western blot was performed as previously described15. ECL system (NCM Biotech) was used to visualize the signals. GAPDH was used as a loading control.

Enzyme-linked immunosorbent assay (ELISA)

To detect the secreted CCL14 levels, cell culture supernatants were harvested after 48 h and analyzed using HCC-1/CCL14 Human ELISA Kit (Raybiotech) according to the manufacturer’s protocols.

CCL14 overexpression and downregulation

Stable over-expression of CCL14 in LM3 was constructed by recombinant Lentivirus encoding CCL14. Blank lentivirus was used as vector control. The knockdown of CCL14 in Huh7 cells was constructed by transfecting specific siRNA with Lipofectamine 2000 (Invitrogen) according to manufacturer’s instructions. The siRNA target sequences were as follows: siRNA-1: CCAUCGCCCUAGGGACCAATT; siRNA-2: CCAACAGCC AGUGCUCCAATT.

CCK-8 colony formation assay and BrdU assay

The CCK8 assay was performed as previously described16. BrdU assay was performed according to the manufacturer’s instructions.

Flow cytometric analysis

Flow cytometric analysis was used to detect cell cycle and apoptosis as described previously17. Apoptosis was measured using FITC-AnnexinV Apoptosis Detection system (BD Bioscience) according to the manufacturer’s instructions.

Tumor bearing animal models in nude mice

LM3 or Huh7 cells with different CCL14 expression levels were harvested and suspended in serum-free DMEM. Athymic nude mice (4–6 weeks old) were divided into four groups: (1) CCL14 group (n = 5), each mouse injected into the lower back with 2 × 106 CCL14 overexpressed LM3 cells; (2) Vector group(n = 5), each mouse injected with 2 × 106 blank vector infected LM3 cells; (3) si-NC group (n = 5), each mouse injected into the lower back with 3 × 106 Huh7 cells treated with siRNA control; (3) siRNA2 group (n = 5), each mouse injected into the lower back with 3 × 106 Huh7 cells threated with CCL14 siRNA. Every 6 days, tumors were monitored and measured. At 42nd day, the mice were sacrificed and tumors weight were examined.

Statistical analysis

The results were expressed as the means ± SD and were considered to be statistically significant at p < 0.05. The data were analyzed using IBM SPSS Statistics 20 (IBM Corporation, USA). Student’s t test was used for comparisons between groups. Categorical data were analyzed by the chi-square or Fisher’s exact tests. Kaplan–Meier analyses and log-rank tests were used to perform survival analyses.

Results

CCL14 is downregulated in HCC tissues and CCL14 low expression is associated with a poor prognosis in clinical patients

CCL14 expression profile was accessed by IHC in a human TMA containing 171 paired HCC and peritumor tissues and representative images were shown in Fig. 1a. The results indicated that CCL14 were scored as negative or weak expression in 42.69% (73 of 171: negative, n = 5; weak, n = 68) of HCC tissues, as compared with 24.56% of corresponding peritumor tissues (42 of 171: negative, n = 3; weak, n = 39; P = 0.0112; Fig. 1b). Twenty pairs of frozen tissues from HCC patients were randomly chosen to examine CCL14 protein expression. Western blot analysis showed that the protein level of CCL14 was remarkably lower in HCC tissues than in adjacent tissues, as shown in representative six pairs (Fig. 1c).

Fig. 1. Relative CCL14 expression in HCC tissues and its clinical significance.

Fig. 1

Open in a new tab

a Representative images of TMA stained with IHC for CCL14. Scale bar, ×400, 50 μm. b The CCL14 protein expression of hepatocellular carcinoma and peritumor tissues in TMA was analyzed. c The CCL14 protein expression in representative six pairs of hepatocellular carcinoma tissues and representative bands are shown. d Kaplan–Meier curves for overall survival from 171 HCC patients according to CCL14 expression in TMA. e Prognostic value of CCL14 in high differentiation, liver cirrhosis, and no tumor capsule subgroups

All patients in the TMA were classified into the CCL14low group or CCL14high group according to CCL14 expression. The results showed CCL14 low expression was associated with a poorer prognosis by Kaplan–Meier analysis (Fig. 1d). The predictive value of CCL14 were also observed in high differentiation (P = 0.026), liver cirrhosis (P = 0.003) and no tumor capsule (P = 0.024) subgroups (Fig. 1e). Additionally, as shown in Table 1, low expression of CCL14 was also associated with microvascular invasion (P = 0.039).

Table 1.

Association of CCL14 expression with clinical parameters of 171 HCC patients

Clinical characteristic CCL14Low no. CCL14High no. P-value
Age (no.) 0.478
<60 54 74
≥60 19 24
Gender 0.268
Male 61 77
Female 12 21
Tumor differentiation 0.195
I–II 8 6
III–IV 65 92
Tumor size (cm) 0.217
<5 41 62
≥5 32 36
Tumor number 0.201
Single 59 85
Multiple 14 13
TNM stage 0.172
I–II 62 89
III–IV 11 9
BCLC stage
0–A 26 44 0.144
B–C 47 54
Microvascular invasion 0.039*
No 41 69
Yes 32 29
Tumor capsule 0.276
No 37 44
Yes 36 54
History of cirrhosis 0.107
No 12 25
Yes 61 73
Open in a new tab

*Statistically significant

A significant association between the CCL14 expression signature and OS in the univariable Cox regression model was also observed. As shown in Table 2, the HR value of the CCL14 low group vs. the CCL14high group for OS was 0.631 (P = 0.037). At the same time, tumor size (HR = 1.890; P = 0.004), microvascular invasion (HR = 1.971; P = 0.002), TNM stage (HR = 2.273; P = 0.004), and BCLC stage (HR = 1.839; P = 0.010) were contributing factors to a shorter OS of patients.

Table 2.

Univariate and multivariate analysis of CCL14 in OS of 171 HCC patients

Variables Univariate analysis Multivariate analysis
HR 95%CI P-value HR 95%CI P-value
Age,year <60 vs. ≥60 1.561 0.988–2.465 0.056 NA
Gender Male vs. female 0.921 0.540–1.571 0.762 NA
Tumor size (cm) ≤5 vs. >5 1.890 1.225–2.915 0.004* 1.749 0.891–3.432 0.104
Tumor number Mutiple vs. single 1.682 0.986–2.870 0.056 NA
Tumor differentiation I–II vs. III–IV 2.109 0.772–5.760 0.146 NA
Microvascular invasion Yes vs. no 1.971 1.276–3.045 0.002* 1.899 1.039–3.471 0.037*
Tumor capsule Yes vs. no 1.208 0.783–1.863 0.393 NA
History of cirrhosis Yes vs. no 1.155 0.698–1.912 0.576 NA
TNM stage I–II vs. III–IV 2.273 1.297–3.983 0.004* 1.522 0.802–2.890 0.199
BCLC stage 0–A vs. B–C 1.839 1.154–2.930 0.010* 0.747 0.323–1.727 0.495
CCL14 Low vs. high 0.631 0.409–0.973 0.037* 0.703 0.452–1.094 0.118
Open in a new tab

Note: Univariate and multivariate analyses, Cox proportional hazards regression model

OS overall survival time, HR hazard ratio, CI confidence interval, NA not applicable

*Statistically significant

Overexpression of CCL14 inhibits the proliferation of HCC cells in vitro

The expression of CCL14 in different human HCC cell lines were tested by western blot, including SMMC-7721, Huh-7, HepG2, Hep3B, MHCC-97L, MHCC-97H, and HCCLM3. It revealed that CCL14 was highly expressed in Huh-7 cells while lowly expressed in LM3 cells (Fig. 2a). CCL14 expression and secretion were both successfully enhanced by recombinant lentivirus in LM3 cells, whereas knocked down in Huh7 cells by siRNA (Fig. 2b, Supplementary Fig. 1). Because siRNA2 sequences played more specific functions, we choose siRNA2 for the following tests. Over-expression of CCL14 significantly reduced the growth rate of LM3 cells, which was revealed by CCK8 assays (Fig. 2c). On the contrary, down-regulation of CCL14 by siRNA2 significantly increased the growth rate in Huh7 cells (Fig. 2d). At the same time, the over-expression of CCL14 in LM3 cells decreased the colonies, while downregulation of CCL14 in Huh7 cells increased the colonies (Fig. 2e). Additionally, CCL14 overexpression in LM3 decreased the proportion of BrdU-incorporated cells, while CCL14 knockdown in Huh7 increased the proportion of BrdU-incorporated cells (Fig. 2f).

Fig. 2. CCL14 inhibits the proliferation of HCC cells in vitro.

Fig. 2

Open in a new tab

a CCL14 were measured by Western blot in six HCC cell lines, including SMMC-7721, Huh-7, HepG2, Hep3B, MHCC-97L, MHCC-97H, and HCCLM3. b CCL14 was overexpressed in LM3 cells by recombinant lentivirus encoding CCL14 (CCL14 group) and knocked down by two siRNA-specific sequences targeting CCL14 in Huh7 cells (siRNA1, siRNA2 groups), which were confirmed by Western blot. siRNA2 sequences played more specific functions. Vector group means LM3 cells were infected by blank lentivirus as control group. si-NC group means Huh7 cells were infected by non-specific siRNA for CCL14 as normal control group. c Over-expression of CCL14 significantly reduced the growth rate of LM3 cells by CCK8 assays. d Down-regulation of CCL14 by siRNA significantly increased the growth rate in Huh7 cells by CCK8 assays. e Overexpression of CCL14 in LM3 cells increased the bacterial colonies, whereas downregulation of CCL14 in Huh7 cells decreased the bacterial colonies. f Representative micrographs and quantification of BrdU incorporation in the indicated cells. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001

CCL14 modulates cell cycle and promotes apoptosis in vitro

CCL14-mediated changes in cell cycle progression and apoptosis were accessed by flow cytometry analysis. Overexpression of CCL14 in LM3 increased both the percentage of G0/G1 phase cells and the rate of apoptosis cells (Fig. 3a, *P < 0.05, **P < 0.01). Knock-down of CCL14 in Huh7 decreased the percentage of G0/G1 phase cells and the rate of apoptosis cell (Fig. 3b, *P < 0.05, **P < 0.01). These data indicated that CCL14 suppressed HCC cell proliferation by inhibiting cell cycle progression and promoting apoptosis in HCC cells.

Fig. 3. CCL14 modulates cell cycle and promotes apoptosis.

Fig. 3

Open in a new tab

a Overexpression of CCL14 in LM3 increased the percentage of G0/G1 phase cells and the rate of apoptosis cells by flow cytometry analysis. b Knock-down of CCL14 in Huh7 decreased the percentage of G0/G1 phase cells and the rate of apoptosis cell by flow cytometry analysis. *P < 0.05, **P < 0.01

Overexpression of CCL14 inhibits the tumor growth in nude mice in vivo

In tumor-bearing animal models, we found tumor grew slowly in CCL14-overexpressed group than control group (Fig. 4a). Both tumor volume and weight were decreased at the same time (Fig. 4b, c). Consistently, tumors of siRNA2 group grew faster and bigger than si-NC group (Fig. 4d–f). Moreover, IHC analysis confirmed that CCL14 over-expressed tumors displayed lower PCNA and BCL2 staining (Fig. 4g). Our results indicate that CCL14 suppresses HCC growth in vivo.

Fig. 4. CCL14 inhibits tumor growth of HCC in nude mice in vivo.

Fig. 4

Open in a new tab

a Images of excised tumors from five nude mice at 42 days. Compared to control vector group, tumors were smaller in CCL14 group. b Tumor-bearing animal models (n = 5) were constructed. The tumor volumes were measured every 6 days. Tumor grew slowly in CCL14 group than control vector group. c The tumor weight was decreased in CCL14 group. d Images of si-NC group and siRNA2 group tumors at 42 days. Compared to si-NC group, tumors were bigger in siRNA2 group. e Tumor grew faster in siRNA2 group than si-NC group. f The tumor weight was increased in siRNA2 group. g Representative graphs of H&E staining and immunohistochemical staining for PCNA and BCL2 in sections. Tumor sections of CCL14 group displayed lower PCNA and BCL2 staining. **P < 0.01, ***P < 0.001, ****P < 0.0001

CCL14 inhibits the proliferation of HCC cells via Wnt/β-catenin-signaling pathway

The expression of several key proteins of Wnt/β-catenin pathway in HCC cells were analyzed. Overexpression of CCL14 decreased the expression of p-GSK3β (S9), β-catenin, cyclin D1, and c-Myc in LM3 cells (Fig. 5a). On the contrary, down-regulation of CCL14 by siRNA significantly increased the expression of these proteins in Huh7 cells (Fig. 5b). In HCC samples, CCL14 expression also showed negatively correlated with cyclin D1 levels (as shown in Supplementary Fig. 2).

Fig. 5. Regulation of Wnt/β-catenin signaling pathway by CCL14.

Fig. 5

Open in a new tab

a Several key proteins of the Wnt/β-catenin-signaling pathway were analyzed by western blot in LM3 cells. Over-expression of CCL14 by Lentivirus decreased the expression of p-GSK3β (S9), β-catenin, cyclin D1, and c-Myc. b Western blot analyses were also performed to test Wnt/β-catenin-signaling pathway in Huh7 cells. Down-regulation of CCL14 by siRNA2 significantly increased the expression of p-GSK3β (S9), β-catenin, cyclin D1, and c-Myc. c Representative images of immunohistochemical staining for cyclinD1 and c-Myc in TMA. CCL14 expression was negatively correlated with cyclinD1 and c-Myc levels. **P < 0.01, ***P < 0.001, ***P < 0.001

Dickkopf1 (DKK1), the specific inhibitor of Wnt/β-catenin-signaling pathway was used to investigate whether CCL14 inhibits the proliferation of tumor cells via Wnt/β-catenin pathway. In LM3 cells, as shown in Fig. 6a, c, compared with blank-vector control, over-expression of CCL14 decreased the expression of cyclinD1 and c-Myc, at the same time, significantly inhibited the proliferation of LM3 cells (**P < 0.01). The combination of CCL14 and DKK1 caused highest inhibition effect (****P < 0.0001).

Fig. 6. CCL14 inhibited proliferation of HCC cells via Wnt/β-catenin-signaling pathway.

Fig. 6

Open in a new tab

a LM3 cells were transfected with control vector and CCL14-lentivirus, treated with DKK1 and harvested for Western blot assay. b Huh7 cells transfected with si-NC and siRNA2, treated with DKK1 and harvested for Western blot assay. c LM3 cells were transfected with control vector and CCL14-lentivirus, treated with DKK1 and detected by CCK8 assay. d Huh7 cells transfected with si-NC and siRNA2, treated with DKK1 and detected by CCK8 assay. **P < 0.01, ***P < 0.001, ****P < 0.0001

On the other hand, in Huh7 cells, as shown in Fig. 6b, d, compared with si-NC control transfection, CCL14 knocking-down by siRNA2 transfection lead to an increase of cyclinD1 and c-Myc, as well as the increased proliferation (***P < 0.001). The combination of DKK1 played an opposite inhibition effect (**P < 0.01).

Additionally, we also explored the potential mechanisms that may lead to CCL14 downregulation in HCC and found that CCL14 levels can be restored by DNA demethylation agent 5-Aza-CdR and histone demethylase inhibitor GSK-467 (Supplementary Fig. 3), indicating the low level of CCL14 is partially the result of epigenetic regulation.

Discussion

CCL14 induces monocytes, macrophages, and THP-1 cells by binding to CCR1, CCR3, and CCR518. Previous reports have shown that CCL14 is also involved in the pathogenesis and progression of various disorders, including allergic airway inflammation and some cancers19–21.

In this study, we examined the expression of CCL14 in paired HCC tumor tissue and peritumor tissues. The results showed that CCL14 low expression in HCC tumor tissues was correlated with poor survival. We also found overexpression of CCL14 inhibited proliferation and promoted the apoptosis of LM3 cells. Knock-down of CCL14 showed opposite effects in Huh7 cells. Moreover, CCL14 suppressed tumor growth in animal models. So CCL14 suppresses the progression and promotes the apoptosis of HCC cells, which contribute to longer OS in HCC patients. In addition, consistent with previous research that reported CCL14 expression was suppressed by JARID1B/LSD1/NuRD complex in breast cancer21, we found CCL14 expression was upregulated after being treated with DNA demethylation agent 5-Aza-CdR or histone demethylase inhibitor GSK-467. These results suggested that epigenetic regulation play critical role in the expression of CCL14 and we will explore more detailed mechanisms subsequently.

The Wnt/β-catenin pathway has been found in various cancer types, including HCC22–24. Previous studies have reported that β-catenin plays an important role in Wnt/β-catenin signaling. When Wnt proteins bind to the receptor, β-catenin will translocate to the nucleus and interact with TCF/LEF transcription factors to regulate downstream gene expression25. In the present study, we showed that knocking-down CCL14 could increase p-GSK3β (S9), β-catenin (S33/S37), and further promote the expression of c-myc and cyclin D1, which are the downstream target genes of Wnt/β-catenin and associated with tumor cell proliferation or apoptosis in various cancers26–28. Our results also suggested that CCL14 exerts its regulatory effects on proliferation of HCC cells through the Wnt/β-catenin pathway by the treatment of DKK1, the specific inhibitor of Wnt/β-catenin pathways.

These findings suggest CCL14 is a novel prognostic factor of HCC and serve as a tumor suppressor.

Supplementary information

Supplementary Figure 1 (11.5MB, tif)
Supplementary Figure 2 (10MB, tif)
Supplementary Figure 3 (12MB, tif)
41419_2019_1966_MOESM4_ESM.docx (44KB, docx)

Figure Legends for Supplementary Figures

Acknowledgements

This work was supported by National Natural Science Foundation of China (31471147, 31971111).

Conflict of interest

The authors declare that they have no conflict of interest.

Footnotes

Edited by I. Amelio

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Mengxuan Zhu, Weiyue Xu, Chuanyuan Wei

Contributor Information

Binbin Liu, Email: liu.binbin@zs-hospital.sh.cn.

Chunmin Liang, Email: cmliang@fudan.edu.cn.

Supplementary information

Supplementary Information accompanies this paper at (10.1038/s41419-019-1966-6).

References

  • 1.Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015;136:E359. doi: 10.1002/ijc.29210. [DOI] [PubMed] [Google Scholar]
  • 2.Zlotnik A, Yoshie O. The chemokine superfamily revisited. Immunity. 2012;36:705. doi: 10.1016/j.immuni.2012.05.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Arakaki R, et al. CCL2 as a potential therapeutic target for clear cell renal cell carcinoma. Cancer Med. 2016;5:2920. doi: 10.1002/cam4.886. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Fang WB, et al. CCL2/CCR2 chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein- and p42/44 mitogen-activated protein kinase (MAPK)-dependent mechanisms. J. Biol. Chem. 2012;287:36593. doi: 10.1074/jbc.M112.365999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Long H, et al. CD133+ ovarian cancer stem-like cells promote non-stem cancer cell metastasis via CCL5 induced epithelial-mesenchymal transition. Oncotarget. 2015;6:5846. doi: 10.18632/oncotarget.3462. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Long H, et al. Autocrine CCL5 signaling promotes invasion and migration of CD133+ ovarian cancer stem-like cells via NF-kappaB-mediated MMP-9 upregulation. Stem Cells. 2012;30:2309. doi: 10.1002/stem.1194. [DOI] [PubMed] [Google Scholar]
  • 7.Wolf MJ, et al. Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway. Cancer Cell. 2012;22:91. doi: 10.1016/j.ccr.2012.05.023. [DOI] [PubMed] [Google Scholar]
  • 8.Lu J, et al. Antitumor efficacy of CC motif chemokine ligand 19 in colorectal cancer. Dig. Dis. Sci. 2014;59:2153. doi: 10.1007/s10620-014-3138-y. [DOI] [PubMed] [Google Scholar]
  • 9.Sand LG, Berghuis D, Szuhai K, Hogendoorn PC. Expression of CCL21 in Ewing sarcoma shows an inverse correlation with metastases and is a candidate target for immunotherapy. Cancer Immunol. Immunother. 2016;65:995. doi: 10.1007/s00262-016-1862-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Chen L, et al. Combination of SLC administration and Tregs depletion is an attractive strategy for targeting hepatocellular carcinoma. Mol. Cancer. 2013;12:153. doi: 10.1186/1476-4598-12-153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Liang CM, et al. Local expression of secondary lymphoid tissue chemokine delivered by adeno-associated virus within the tumor bed stimulates strong anti-liver tumor immunity. J. Virol. 2007;81:9502. doi: 10.1128/JVI.00208-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Shi JY, et al. CC chemokine receptor-like 1 functions as a tumour suppressor by impairing CCR7-related chemotaxis in hepatocellular carcinoma. J. Pathol. 2015;235:546. doi: 10.1002/path.4450. [DOI] [PubMed] [Google Scholar]
  • 13.Lane D, et al. CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling. Mol. Cancer. 2016;15:58. doi: 10.1186/s12943-016-0542-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Wei C, et al. Upregulation of UHRF1 promotes the progression of melanoma by inducing cell proliferation. Oncol. Rep. 2018;39:2553. doi: 10.3892/or.2018.6356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Yanru W, et al. Transcriptomic analyses of chemokines reveal that down-regulation of XCR1 is associated with advanced hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 2018;496:1314. doi: 10.1016/j.bbrc.2018.02.008. [DOI] [PubMed] [Google Scholar]
  • 16.Kurita K, et al. TRIP13 is expressed in colorectal cancer and promotes cancer cell invasion. Oncol. Lett. 2016;12:5240. doi: 10.3892/ol.2016.5332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Chen W, et al. Silencing Trim59 inhibits invasion/migration and epithelial-to-mesenchymal transition via TGF-beta/Smad2/3 signaling pathway in bladder cancer cells. Onco Targets Ther. 2017;10:1503. doi: 10.2147/OTT.S130139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Tsou CL, et al. Identification of C-C chemokine receptor 1 (CCR1) as the monocyte hemofiltrate C-C chemokine (HCC)-1 receptor. J. Exp. Med. 1998;188:603. doi: 10.1084/jem.188.3.603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Gupta S, et al. n-Nonanoyl-CCL14 (NNY-CCL14), a novel inhibitor of allergic airway inflammation is a partial agonist of human CCR2. Allergy. 2008;63:1317. doi: 10.1111/j.1398-9995.2008.01787.x. [DOI] [PubMed] [Google Scholar]
  • 20.Vyshkina T, et al. CCL genes in multiple sclerosis and systemic lupus erythematosus. J. Neuroimmunol. 2008;200:145. doi: 10.1016/j.jneuroim.2008.05.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Li Q, et al. Binding of the JmjC demethylase JARID1B to LSD1/NuRD suppresses angiogenesis and metastasis in breast cancer cells by repressing chemokine CCL14. Cancer Res. 2011;71:6899. doi: 10.1158/0008-5472.CAN-11-1523. [DOI] [PubMed] [Google Scholar]
  • 22.Chen J, et al. The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/beta-catenin signalling pathway. Gut. 2016;65:1522. doi: 10.1136/gutjnl-2015-310625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Li L, Yang WT, Zheng PS, Liu XF. SOX17 restrains proliferation and tumor formation by down-regulating activity of the Wnt/beta-catenin signaling pathway via trans-suppressing beta-catenin in cervical cancer. Cell Death Dis. 2018;9:741. doi: 10.1038/s41419-018-0782-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Mao J, et al. Roles of Wnt/beta-catenin signaling in the gastric cancer stem cells proliferation and salinomycin treatment. Cell Death Dis. 2014;5:e1039. doi: 10.1038/cddis.2013.515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Nejak-Bowen KN, Monga SP. Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. Semin. Cancer Biol. 2011;21:44. doi: 10.1016/j.semcancer.2010.12.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 1993;7:812. doi: 10.1101/gad.7.5.812. [DOI] [PubMed] [Google Scholar]
  • 27.Griffin NI, et al. ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC. Breast Cancer Res. 2016;18:113. doi: 10.1186/s13058-016-0770-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Wu K, et al. EYA1 phosphatase function is essential to drive breast cancer cell proliferation through cyclin D1. Cancer Res. 2013;73:4488. doi: 10.1158/0008-5472.CAN-12-4078. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Figure 1 (11.5MB, tif)
Supplementary Figure 2 (10MB, tif)
Supplementary Figure 3 (12MB, tif)
41419_2019_1966_MOESM4_ESM.docx (44KB, docx)

Figure Legends for Supplementary Figures

Articles from Cell Death & Disease are provided here courtesy of Nature Publishing Group

RESOURCES